Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBI3016 in Mild to Moderate Hypertensive Patients
NCT07352969Phase 2Active, not recruiting
- Sponsor
- Innovent Biologics
- Start
- Feb 2026
- Primary completion
- Mar 2029
- Modality
- Conjugated siRNA, Chemically Modified siRNA
- Countries
- 1
01
Overview
A Phase 2 trial of IBI3016 in hypertension (HTN), sponsored by Innovent Biologics. Started Feb 2026; status: active, not recruiting.
02
Drugs
IBI3016
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT07352969.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07352969.